CTOs on the Move

Aegis Sciences

www.aegislabs.com

 
Aegis Sciences Corporation is a toxicology laboratory specializing in forensic and healthcare services that provides science-driven testing and consulting for clients, such as professional and amateur sports organizations, distinguished college and university athletic programs, healthcare professionals, Fortune 500 companies, medical examiners, and government agencies throughout the United States. Aegis developed and has specialized in Zero Tolerance Drug Testing® services to ensure workplaces and sports programs are truly drug free. Since its inception as a sports anti-doping lab at Vanderbilt University, Aegis has helped keep athletes clean and in the game.
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million
  • www.aegislabs.com
  • 515 Great Circle Road
    Nashville, TN USA 37228
  • Phone: 615.255.2400

Executives

Name Title Contact Details
Tim Ryan
Chief Information Officer Profile

Similar Companies

Precision Therapeutics

Precision Therapeutics is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MicroTest Laboratories

MicroTest Laboratories is a Agawam, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

KineMed

KineMed is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Radiology Associates

American Radiology Associates is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DiaDexus

Diadexus is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. We pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating this biomarker`s utility. Our products are the only two FDA-cleared tests to measure Lp-PLA2: The PLAC® Test ELISA Kit first cleared by the FDA in 2003 and The PLAC® Test for Lp-PLA2 Activity cleared in December 2014. Our pipeline of advanced cardiac biomarkers includes biomarkers for heart failure, proADM, proET-1 and proANP. Each marker gives distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. Our portfolio of advanced cardiac biomarkers is available to be paired with novel therapeutics in development for indications where cardiovascular risk information would provide valuable insights. This information can be used by pharmaceutical companies in targeting the appropriate patient population and understanding the potential long-term side effects for their therapeutics, potentially avoiding long-term follow up studies.